Univariable analysis of GRFS
| . | KMT2A (n = 426) . | Intermediate (n = 2384) . | Adverse (n = 969) . | . | |||
|---|---|---|---|---|---|---|---|
| Outcomes . | n . | Prob (95% CI) . | n . | Prob (95% CI) . | n . | Prob (95% CI) . | P value . |
| GVHD-free, relapse-free survival | 410 | — | 2326 | — | 948 | — | <.001 |
| 1 | 72 | 21 (17-25) | 527 | 27 (25-29) | 150 | 19 (16-21) | <.001 |
| 3 | 26 | 12 (9-16) | 187 | 17 (15-19) | 54 | 10 (8-12) | <.001 |
| 5 | 13 | NE | 103 | 15 (13-16) | 39 | 9 (7-11) | <.001 |
| . | KMT2A (n = 426) . | Intermediate (n = 2384) . | Adverse (n = 969) . | . | |||
|---|---|---|---|---|---|---|---|
| Outcomes . | n . | Prob (95% CI) . | n . | Prob (95% CI) . | n . | Prob (95% CI) . | P value . |
| GVHD-free, relapse-free survival | 410 | — | 2326 | — | 948 | — | <.001 |
| 1 | 72 | 21 (17-25) | 527 | 27 (25-29) | 150 | 19 (16-21) | <.001 |
| 3 | 26 | 12 (9-16) | 187 | 17 (15-19) | 54 | 10 (8-12) | <.001 |
| 5 | 13 | NE | 103 | 15 (13-16) | 39 | 9 (7-11) | <.001 |
Univariable analysis of GRFS by translocation partner is not provided, as not enough cases remained at risk at 1 y (most events occurred earlier).